RNA interference (RNAi) is a biological process that silences genes at the post-transcriptional level in a highly specific manner. Many biotechnology companies are exploring RNAi for therapeutic purposes. ORCA Therapeutics’ portfolio comprises technologies to deliver RNAi-mediating molecules using oncolytic viruses and proprietary technology to reactivate endogenous p53 in cancer cells by silencing p53 inhibitors.
Our technology platform includes methods to identify virus inhibitory factors in cancer cells and to construct oncolytic viruses that silence these factors. ORCA Therapeutics’ technology is used to screen RNAi libraries for inhibitors of oncolysis in specific cancer types. This will expand ORCA Therapeutics’ repertoire of proprietary oncolytic agents.
Publication:
Carette et al. (2004) Cancer Res. 64, 2663-2667.